Precision launches $80.5m public offering:
This article was originally published in Clinica
Executive Summary
Precision Therapeutics, the developer of the ChemoFx test for assessing the efficiency of various cancer therapies, is aiming to raise $80.5m through a public flotation on the Nasdaq stock exchange. The Pittsburgh, Pennsylvania-based firm did not disclose the amount of shares offered or the price range expected for the IPO, but it did indicate that the proceeds would be split between expansion of ChemoFx's sales and marketing capabilities, the funding of R&D programmes and clinical studies, and general corporate expenses, including the potential expansion of laboratory facilities. Precision posted revenues of $846,000 and a net loss of $8.6m in fiscal 2006. Most recently, it recorded half year revenues of $926,000 for 2007.
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.